Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Role of Personal Identity in Psychotic Symptoms: a Study With the Repertory Grid Technique

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03820362
Recruitment Status : Completed
First Posted : January 29, 2019
Last Update Posted : January 29, 2019
Sponsor:
Collaborators:
Parc Sanitari Sant Joan de Déu
Agència de Gestió d'Ajuts Universitaris i de Recerca, Catalunya, Spain
Ministerio de Educación y Formación Profesional, Spain
Information provided by (Responsible Party):
Helena García Mieres, University of Barcelona

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Personal identity is being recently recognized as a core element for mental health disorders, with relevant clinical implications. However, scarcity of data exists on its role in schizophrenia and related disorders. The repertory grid (RGT), a technique derived from personal construct theory, has been used in different clinical and non-clinical contexts for the study of the construction perception of self and others, to appreciate aspects of interpersonal construing such as polarization and differentiation (unidimensional thinking) or self-construction.and Our study aims to explore the potential influence of the structure of personal identity and of other relevant cognitive factors (social cognition, metacognition, neurocognition) in positive and negative symptoms in people suffering schizophrenia and related disorders.

Condition or disease
Schizophrenia Psychotic Disorders Self

Detailed Description:

Over recent years, the importance of the sense of self and personal identity in psychopathology and its treatment has been highlighted. Several studies inspired in the Personal Construct Psychology framework have found a variety of identity characteristics in clinical conditions such as depression or eating disorders, but the evidence in schizophrenia and other psychotic related disorders is scarce.

In addition, current psychological models of positive and negative symptoms highlight the influence of neurocognition, social cognition and self-concepts in the development and maintenance of psychotic experiences. Despite the recognized need of person-centered approaches to understand psychopathology processes in psychosis, psychological models for explaining psychotic symptoms have not explored sufficiently the role of this kind of person-centered measures.

Aim

1. To examine the influence of the structure of personal identity and other relevant cognitive factors in positive and negative symptoms

Hypotheses

  1. Positive symptoms will be influenced by dichotomous thinking style and construction of self as measured with the RGT.
  2. Negative symptoms will be affected by the richness of the construct system as measured with the RGT.
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 85 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Personal Identity, Cognitive Factors and Psychotic Symptoms in Schizophrenia and Related Disorders: A Cross-sectional Study With the Repertory Grid Technique
Actual Study Start Date : February 2016
Actual Primary Completion Date : November 2018
Actual Study Completion Date : November 2018

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Self-ideal discrepancy, RGT [ Time Frame: 2 hours ]
    Self-esteem. Possible range: 0-0,60. Higher values represent a worse outcome

  2. Self-others discrepancy, RGT [ Time Frame: 2 hours ]
    Perceived social isolation. Possible range: 0-0,60. Higher values represent a worse outcome

  3. Interpersonal construct differentiation, RGT [ Time Frame: 2 hours ]
    Percentage of Variance Accounted for the First Factor. Possible range: 0-100. Higher values represent a worse outcome

  4. Polarization, RGT [ Time Frame: 2 hours ]
    Dichotomous thinking style in the interpersonal context. Possible range: 0-100. Higher values represent a worse outcome

  5. Number of elicited constructs, RGT [ Time Frame: 2 hours ]
    Quantity of constructs that the person is able to express to describe self and others. Possible range: 10-50. Higher values represent a better outcome

  6. Psychotic symptoms (PANSS, Kay et al. 1987; Peralta & Cuesta, 1994). [ Time Frame: 40 minutes ]
    Positive and negative symptoms of psychosis. Range: 7-112. Higher values represent a worse outcome.

  7. Metacognition: BCIS (Beck et al. 2004; Gutiérrez-Zotes et al. 2012); Garety et al, 1991; Dudley et al, 1997) [ Time Frame: 15 minutes ]
    Cognitive insight. Range: 0-45. Higher values represent a better outcome

  8. Theory of mind: the Hinting Task (Corcoran et al., 1995; Gil-Sanz et al., 2012) [ Time Frame: 5 minutes ]
    Possible range: 0-12. Higher values represent a better outcome

  9. General intellectual functioning (WAIS) [ Time Frame: 20 minutes ]
    vocabulary subscale. Range: 70-140. Higher values represent a better outcome

  10. Executive functioning: WSCT (Bergs et al., 1948) [ Time Frame: 15 minutes ]
    Wisconsin Card Sorting Test. Categories completed and perseverative errors. Higher values represent a better outcome


Secondary Outcome Measures :
  1. Sociodemographical data [ Time Frame: 10 minutes ]
    Gender, chronicity, antipsychotic dosage, diagnosis, age, marital status, education level, employment situation

  2. Depressive symptoms [ Time Frame: 10 minutes ]
    Beck Depression Inventory (Beck et al. 1996; Sanz, Perdigón & Vázquez, 2003). Range_ 0-63. High values represent a worse outcome.

  3. General functioning [ Time Frame: 5 minutes ]
    Global Assessment of Functioning (Endicot et al., 1976). Range: 0-100. Higher values represent a better outcome.

  4. Self-esteem [ Time Frame: 5 minutes ]
    Rosenberg self-esteem scale (Martín Albó et al., 2007). Range: 0-40. Higher values represent a better outcome

  5. Social functioning [ Time Frame: 20 minutes ]
    Social Functioning Scale (Birchwood et al., 1990; Torres & Olivares, 2000). Range: Range: 45-195

  6. Psychological distress [ Time Frame: 10 minutes ]
    CORE-OM (Evans et al., 2002; Trujillo et al., 2016). Range: 0-4. Higher values represent a worse outcome

  7. Jumping to Conclusions [ Time Frame: 15 minutes ]
    The beads task (Garety et al., 1991; Dudley et al, 1997). Dichotomous: yes/no. A "yes" represents a worse outcome


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients recruited from the community, suffering schizophrenia and related disorder
Criteria

Inclusion Criteria:

  • diagnosis of schizophrenia, psychotic disorder not otherwise specified, delusional disorder, schizoaffective disorder, brief psychotic disorder, or schizophreniform disorder
  • age between 18 and 60 years.
  • patients from outpatient mental health units

Exclusion Criteria:

  • traumatic brain injury, dementia, or intellectual disability (pre-morbid IQ <70)
  • current substance dependence
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03820362


Locations
Layout table for location information
Spain
Parc Sanitary Sant Joan de Déu
Sant Boi De Llobregat, Barcelona, Spain
Sponsors and Collaborators
University of Barcelona
Parc Sanitari Sant Joan de Déu
Agència de Gestió d'Ajuts Universitaris i de Recerca, Catalunya, Spain
Ministerio de Educación y Formación Profesional, Spain
Investigators
Layout table for investigator information
Principal Investigator: Helena García-Mieres, MsC Universitat de Barcelona & Parc Sanitari Sant Joan de Déu
Study Director: Susana Ochoa, PhD Parc Sanitari Sant Joan de Déu
Study Director: Guillem Feixas, PhD University of Barcelona
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Helena García Mieres, M.Sc., Ph.D. Cand., University of Barcelona
ClinicalTrials.gov Identifier: NCT03820362    
Other Study ID Numbers: FPU15/01721
First Posted: January 29, 2019    Key Record Dates
Last Update Posted: January 29, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Helena García Mieres, University of Barcelona:
personal identity
personal constructs
Additional relevant MeSH terms:
Layout table for MeSH terms
Schizophrenia
Mental Disorders
Psychotic Disorders
Schizophrenia Spectrum and Other Psychotic Disorders